TrkA Inhibitor Compounds with Optimized Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds do not effectively inhibit TrkA, which is involved in various disorders such as pain, cancer, inflammatory, and dermatological diseases, and there is a need for a compound with TrkA inhibitory activity for therapeutic applications.
Innovation Solution
A compound represented by Formula (I) with specific structural features, including various substituents and functional groups, exhibits TrkA kinase inhibitory activity, forming the basis of a pharmaceutical composition for treating TrkA-mediated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing TrkA inhibitor compounds are used, then TrkA inhibitory activity is achieved, but the compounds lack effective therapeutic potential due to insufficient inhibitory activity or poor pharmacological properties
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular parameters of the compound structure, including substituting different groups at specific positions (R1-R15), adjusting molecular weight, and optimizing functional groups to achieve both high TrkA inhibitory activity and desirable pharmacological properties for therapeutic applications
Solution Approach 2:
The invention creates composite molecular structures by combining multiple functional groups and structural motifs ( Formula I compounds with various substituents including heterocyclic groups, carbonyl groups, and linkers) to achieve synergistic effects that simultaneously provide TrkA inhibition and therapeutic efficacy
2Ease of manufacture
If compound structure is simplified for easier synthesis, then manufacturing ease improves, but TrkA inhibitory activity and therapeutic effectiveness deteriorate
Solution Approach 1:
The patent applies segmentation by dividing the complex molecular structure into modular components (core scaffold with specific substituents at defined positions), allowing systematic assembly through stepwise synthesis while maintaining the overall complexity necessary for high TrkA inhibitory activity
Solution Approach 2:
The invention applies local quality by introducing specific functional groups and substituents at particular positions in the molecular structure (e.g., R1-R15 positions) to achieve local chemical properties that are critical for TrkA binding and inhibition, while the rest of the molecule can be optimized for synthesis ease
3Quantity of substance
If compound solubility is improved for better bioavailability, then therapeutic effectiveness improves, but metabolic stability and enzyme inhibition profiles deteriorate
Solution Approach 1:
The patent applies parameter changes by carefully selecting and adjusting molecular parameters including the introduction of polar groups for solubility while incorporating hydrophobic regions and rigid structures to maintain metabolic stability, achieving an optimal balance through systematic structure-activity relationship optimization
Data Source
AI summary
The present invention relates to a compound represented by Formula (I):wherein -L- is —C(═X)—, or the like, —Z— is —NR5—, or the like, —ZA— is —NR5A—, or the like, —W— is —C(R8R9)n-, —WA— is —C(R3R4)m-, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R2 is a hydrogen atom, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.